Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2020-10-28 Board/Management Inform…
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Valberedning i Vitrolife AB (publ)
Board/Management Information Classification · 99% confidence The document is a press release dated October 28, 2020, announcing the composition of the Nomination Committee (Valberedning) for the upcoming Annual General Meeting (AGM) in 2021. It explicitly mentions the date of the AGM (April 28, 2021) and provides instructions for shareholders regarding agenda items. This content directly relates to the preparatory steps and governance surrounding the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R), as it concerns the setup for the AGM.
2020-10-28 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'delårsrapport januari-juni 2020' (Interim Report January-June 2020) for Vitrolife AB. It contains comprehensive financial statements, segment reporting, cash flow analysis, and management commentary for the first half of the fiscal year. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. H1 2020
2020-07-13 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'interim report january-JUNE 2020' and contains comprehensive financial statements, segment reporting, cash flow analysis, and management commentary for the specified period. It is clearly a periodic financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). H1 2020
2020-07-13 English
Report from Annual General Meeting of Vitrolife AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled 'Report from Annual General Meeting of Vitrolife AB (publ)' and details decisions made during that meeting, such as dividend decisions, board re-elections, auditor appointments, remuneration, and authorizations for share issuance/acquisition. This content directly corresponds to the definition of 'AGM Information'. The document length is short (2769 chars), but it is a report *of* the meeting outcomes, not an announcement *about* the upcoming meeting or a general regulatory filing.
2020-06-15 English
Kommuniké från årsstämma i Vitrolife AB (publ)
AGM Information Classification · 99% confidence The document is titled 'Kommuniké från årsstämma i Vitrolife AB (publ)' which translates to 'Communiqué from the Annual General Meeting (AGM) in Vitrolife AB (publ)'. The content details specific resolutions passed at the meeting, such as decisions on dividends, election/re-election of board members, auditor appointment, board remuneration, and authorizations for share issuance/repurchase. These items are characteristic of the formal outcomes announced following an AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (2336 chars) is consistent with a summary communiqué rather than a full presentation or detailed report.
2020-06-15 Swedish
Uppdatering av covid-19 påverkan på Vitrolifes försäljning
Management Reports Classification · 99% confidence The document is a press release dated June 3, 2020, titled "Uppdatering av covid-19 påverkan på Vitrolifes försäljning" (Update on covid-19 impact on Vitrolife's sales). It provides an estimate for Q2 sales (40-50% of the previous year) and discusses the recovery trend. This is a preliminary announcement of financial performance updates outside of a scheduled quarterly report release. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR). It is best classified as an Earnings Release (ER) as it communicates key financial performance highlights for the current period (Q2 estimate) ahead of the formal report, or potentially a Regulatory Filing (RNS) if it's an unscheduled market update. Given the specific focus on sales estimates and performance outlook, 'ER' (Earnings Release) is the most appropriate fit, as it communicates key financial results/expectations. The final sentence confirms it is information the company is obliged to disclose under EU market abuse regulation, which supports a regulatory classification, but the content is purely financial performance related.
2020-06-03 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.